ZURICH (Reuters) – Novartis has launched an external review into the safety of its blindness medicine Beovu after the American Society of Retinal Specialists (ASRS) raised concerns.
The Swiss drugmaker’s shares fell nearly 3% in early trading after the ASRS communicated to its members about the drug, a replacement for Novartis’s blockbuster Lucentis.
(Reporting by John Revill; editing by Jason Neely)
